Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

May 2, 2024

NASDAQ US Health Care Biotechnology earnings 48 min

Earnings Call Speaker Segments

Chris Taylor

executive
#1

Thanks, operator. Hello, everyone, and good morning. We're glad to have you with us on Agios' conference call and webcast, where we'll go over our financial results for the first quarter of 2024 along with recent business highlights. Slides for today's call can be found in the Investors section at agios.com. Joining me today are Brian Goff, our Chief Executive Officer; Dr. Sarah Gheuens, who serves as Chief Medical Officer and Head of R&D; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, our Chief Financial Officer. Before we begin, I want to remind all of you that certain statements made during this call will contain forward-looking statements. Due to a range of risks, uncertainties and other factors, including those described in our most recent filings with the SEC and any future filings we may submit to the SEC, actual results and events might differ materially from what those forward-looking statements express or imply. With that said, I'll hand things over to Brian.

Brian Goff

executive
#2

Hello, everyone, and thanks for being here this morning. At Agios, our goal is to create and provide breakthrough therapies that improve and prolong the lives of those dealing with uncommon illnesses, and 2024 has gotten off to a strong beginning for us. What we’re built on now is mitapivat’s innovative way of working, centered on the general well-being of red blood cells, and that has been a major factor behind the clinical outcomes we’ve achieved lately. On January 3rd, we shared encouraging results from the Phase III ENERGIZE trial of mitapivat, our main PK activator sold under the name PYRUKYND, in individuals suffering from nontransfusion-dependent thalassemia. The trial achieved its primary goal of hemoglobin response rate, along with both important secondary goals related to the shift from baseline in FACIT-Fatigue score and mean hemoglobin concentration, and we’re eager to share this information at a forthcoming medical conference. Just to reiterate, nontransfusion-dependent thalassemia makes up roughly 2/3 of thalassemia cases in the U.S. and lacks any FDA-approved therapies. Even though these individuals don’t need routine transfusions, it’s becoming more widely recognized that they face a major toll on their quality of life, numerous severe health complications, and a heightened chance of early death because of ongoing hemolysis and ineffective erythropoiesis. With these findings in hand, our team is busy getting ready for a possible thalassemia launch in the U.S. Alongside the ENERGIZE trial in nontransfusion-dependent thalassemia, we’re continuing to move forward with the Phase III ENERGIZE-T trial of mitapivat in transfusion-dependent thalassemia; we anticipate sharing results from that trial in the second quarter, a somewhat more precise timeline than what we said before, and we intend to file a single regulatory submission with the FDA covering data from both ENERGIZE and ENERGIZE-T before the year is out. At the same time, we’re looking ahead to short-term milestones across a number of other clinical initiatives in our pipeline, such as finishing patient enrollment in the Phase III segment of the RISE UP trial of mitapivat for sickle cell disease before this year ends, and sharing findings from 4 more Phase III trials by the close of 2025. Sarah will give a thorough rundown of our advancements and forthcoming milestones throughout R&D in just a few minutes. Because of the steady stream of favorable results from the mitapivat development program and the substantial unmet needs in the conditions we’re targeting, we think mitapivat could alter the trajectory of various hemolytic anemias by enhancing red blood cell health and grow into a multibillion-dollar franchise. To fully capture mitapivat’s commercial promise and given how strong the ENERGIZE data is, our commercial team is wholly dedicated to expanding on the framework we’ve set up via our existing launch in pyruvate kinase deficiency, or PKD, so we can get ready for possible U.S. launches of mitapivat for thalassemia in 2025 and sickle cell disease in 2026. Tsveta will offer more specifics on the thalassemia market opportunity and the team’s thorough launch preparations, plus an update on our ongoing PKD launch, in a little while. To wrap up, Cecilia will give you details, but our cash situation came out of Q1 in a solid place, showing roughly $714 million across cash and investments on the balance sheet. What's more, there's an opportunity to strengthen that cash standing soon, since Servier shared news that the FDA accepted the filing and granted priority review for a new drug application covering vorasidenib, aimed at treating specific IDH mutant diffuse glioma. As you may remember, when Agios sold its oncology business to Servier, Agios kept the right to a possible $200 million milestone if the FDA approves vorasidenib, plus 15% royalties on potential U.S. net sales. Should it get approved, vorasidenib would be a first-in-class targeted therapy for patients dealing with IDH mutant gliomas, and we're anticipating the PDUFA action date of August 20, 2024. With that, I'll hand things over to Sarah.

Sarah Gheuens

executive
#3

Thanks, Brian. Since we're about to see the top-line data readout for the Phase III ENERGIZE-T study of mitapivat in transfusion-dependent thalassemia, I'd like to highlight a few key points about the mitapivat development program in thalassemia. As a reminder, the Phase III program for mitapivat in thalassemia — ENERGIZE and ENERGIZE-T — was designed so that the data would span all thalassemia subpopulations, including alpha and beta thalassemia, plus groups whose transfusion needs differ. As Brian mentioned, only those patients with transfusion-dependent beta thalassemia — who represent 1/3 of U.S. patients — have an FDA-approved treatment option at present. The remaining 2/3 of patients in the U.S., which includes every patient with alpha thalassemia along with those with beta thalassemia who are nontransfusion dependent, have nothing approved. A frequent misunderstanding is that nontransfusion dependent, or NTD, thalassemia patients are not as ill. The truth, though, is that these individuals endure a poor quality of life and a higher rate of serious morbidities, such as thrombosis and premature death. This population, accounting for roughly 2/3 of all thalassemia patients in the U.S., faces a high unmet need for any treatment; that unmet need was strongly confirmed through our Phase III ENERGIZE study by how quickly enrollment went, the total number of patients enrolled and the high completion and rollover rates we observe; we were very pleased to announce positive results from this study in January and are eagerly awaiting the opportunity to present more complete results at an upcoming medical meeting. Now to those results. What we intend to do is take what we learned in Phase II and apply a stricter approach to assessing how hemoglobin responds during the Phase III ENERGIZE trial. In that study, we set the primary endpoint as a rise of at least 1 gram per deciliter in mean hemoglobin levels measured between week 12 and week 24 relative to baseline — only this time the trial is considerably bigger. We were glad to share that this trial met its goal: taking 100 milligrams of mitapivat twice daily produced a strongly statistically significant outcome for the primary endpoint, hemoglobin response rate. In the treatment group, 42.3% of patients reached a hemoglobin response, compared with 1.6% in the placebo group. Mitapivat treatment also led to statistically significant gains on both key secondary endpoints, among them a shift from baseline in the average FACIT-Fatigue score, a meaningful patient-reported gauge of how patients feel. Because mitapivat works through a new mechanism that boosts the general health of red blood cells, it became the first molecule to demonstrate in a randomized controlled trial that it not only raises hemoglobin but also reduces how fatigued thalassemia patients feel. Beyond that, every prespecified subgroup analysis, looking at both primary and secondary endpoints, came out in favor of mitapivat over placebo, which tells us that no particular subgroup was driving the results — this backs our plan to seek a broad label encompassing all subtypes of thalassemia. Now shifting to ENERGIZE-T: there are three key reasons I'd like to go through for why we feel excited about the data readout that's approaching in transfusion-dependent thalassemia. To start, we should keep in mind that no matter what level of transfusion support a patient requires, thalassemia is a hemolytic anemia. Mitapivat's novel way of working raises PK activity and boosts the overall health of red blood cells, which means it gets right at the hemolysis pathophysiology underlying every thalassemia subtype. Next, this mirrors the strategy we pursued in our PK deficiency program. There, in the Phase III ACTIVATE-T trial of mitapivat involving regularly transfused adults who had pyruvate kinase deficiency, the drug produced a statistically significant and clinically meaningful decrease in transfusion burden. That data, plus positive results from the Phase III ACTIVATE study involving PK deficiency patients who don't receive routine transfusions, led the FDA to approve mitapivat for adults with PK deficiency regardless of whether they need transfusions, and we're excited about the opportunity to achieve the same outcome in thalassemia. Last, in line with mitapivat's mechanism of action, we've seen consistent data demonstrating gains in hemolysis and ineffective erythropoiesis across trials covering 3 hemolytic anemias: PK deficiency, sickle cell disease and nontransfusion-dependent thalassemia. Before we go further, let me restate what ENERGIZE-T is measuring as its main goal: a transfusion reduction response. That means a patient's transfused red blood cell units drop by at least half, and the drop equals or exceeds 2 units of transfused red blood cells across any 12-week stretch that runs consecutively, continuing through week 48, measured against where they started. Under this definition, patients can lower their transfusion burden in 2 possible ways. One route is longer gaps in time between transfusions; the other is using fewer units, or a combination of both. So that the standard of care would be as consistent as possible across this large global trial, each patient received an individualized hemoglobin threshold value, derived from their personal transfusion history, prior to enrollment. For every patient, that particular hemoglobin cutoff determines the level at which a transfusion would be given while the trial is running. Because mitapivat works by targeting red blood cell health and reducing hemolysis, the goal is to hold hemoglobin above that cutoff and reduce how often transfusions are required. Insights from prior studies, together with input from regulators, shaped how we designed this trial, and we feel the primary endpoint's dynamic assessment period reflects the outcomes that matter to patients, physicians, and regulators alike. We've moved our expectation for when this study will report results to the second quarter. Our intention is to send one submission to the FDA that includes findings from both ENERGIZE and ENERGIZE-T, and we expect to do so before this year is over. The label we're pursuing would apply to patients across every thalassemia subtype. Now, on to sickle cell disease. Recruitment into the Phase III cohort of the RISE UP trial for mitapivat keeps moving forward, and we remain on schedule to finish signing up patients before this year concludes; our confidence keeps building regarding what mitapivat can do in sickle cell disease, since we think it has what it takes to stand out as both the top option and the very first of its kind; we're eager to share top line results from this 52-week trial in the coming year and hold a strong belief that mitapivat can tackle the significant unmet need in this condition by easing anemia, helping patients feel improvement, and lowering painful sickle cell crises. On top of that, we're still on track to reach all the milestones for the rest of our pipeline as it moves forward. This quarter, we started dosing patients in the Phase I study of AG-181, which is an oral phenylalanine hydroxylase, or PAH, stabilizer being developed for phenylketonuria, or PKU — a condition where patients have very limited treatment options. We're excited about the possibility of offering a novel approach to treating PKU, and we look forward to sharing updates on next steps as enrollment grows. Drawing from findings in the Phase IIa trial of our innovative PK activator AG-946 in lower-risk MDS, we intend to raise the dose levels tested in the next Phase IIb trial, which should kick off around the middle of 2024; and for pediatric PK deficiency, we anticipate wrapping up patient enrollment for the Phase III ACTIVATE kids trial around the middle of this year, and we now also anticipate sharing top line results from the Phase III ACTIVATE kids-T trial by mid-2024, earlier than the year-end timeline we initially expected. It's a thrilling period here at Agios, and we're eager to bring you further data and updates as we move forward through this year. Specifically, we can't wait to show you the collection of filings for < > and have them become available to the public in 2 weeks; with that, I'll hand things over now to Tsveta.

Tsveta Milanova

executive
#4

Thanks, Sarah. Right now, receiving a thalassemia diagnosis can feel overwhelming for patients and the people who care for them. No matter which subtype someone has, the choices for treatment are few, and both the toll the disease takes and what it costs to manage are considerable. Every form of thalassemia, including the nontransfusion-dependent type, is tied to elevated rates of serious morbidities, poorer quality of life, and a greater chance of dying prematurely. In the U.S., roughly 6,000 adults have a diagnosed case of thalassemia. About 4,000 of them are nontransfusion dependent, and for those individuals there is nothing available to treat them as of today. As Sarah noted, this group of patients was the focus of our ENERGIZE clinical trial, which showed the benefit of mitapivat in people with nontransfusion-dependent thalassemia. The other 2,000 are transfusion-dependent and have no oral options for treatment. We are looking forward with great anticipation to data from our ENERGIZE-T study in the second quarter, which centers on these transfusion-dependent patients. With mitapivat, our aim is to change how thalassemia is treated by securing the first approval for every subtype of the disease. Buoyed by the positive results from the ENERGIZE study and the possibility of positive results from ENERGIZE-T, our commercial organization is getting ready in earnest to tackle this substantial unmet need, with a possible launch in thalassemia in the U.S. next year. As we have pointed out, the U.S. thalassemia market offers more favorable commercial dynamics than PK deficiency. Beyond the data we are producing through the mitapivat clinical development program, we see 3 key factors that could help drive adoption of mitapivat in thalassemia in the U.S. First, because newborn screening is available and ICD-10 codes are well-established, the diagnosis rate for thalassemia is high, and many patients are diagnosed before they reach adulthood. Second, patients and providers alike are clustered in a limited number of centers, with roughly 50% of all diagnosed patients being treated at fewer than 150 affiliated practices, which gives our initial launch a clear focus. And third, our clinical trial sites in the U.S. are located at some of the main centers of excellence, so a large share of treating physicians will have direct experience with mitapivat. With these data and the mitapivat target product profile, we believe we are well positioned to offer a potential foundational treatment option for thalassemia patients, regardless of subtype. Our team is focused on 4 areas of U.S. launch preparations for thalassemia. First, we keep advancing extensive market research and claims data analysis to further sharpen our market insights and our HCP targeting. Second, we are rolling out a disease education campaign in the coming weeks, designed for both patients and clinicians, highlighting the long-term complications and burden of disease across all thalassemia subtypes, particularly the nontransfusion-dependent patients who suffer from the misconception that they are at less risk. Third, we are carrying out a disciplined expansion of our commercial and medical teams to rightsize the organization for a successful launch in this larger but still rare market. And fourth, our market asset team is already engaging with payers on disease state education. Our team securing widespread market availability for PYRUKYND in PK deficiency makes me very proud, and we expect an equally robust result in thalassemia. Beyond the U.S., our goal is to get the most out of ex-U.S. markets via aligned regulatory submissions, which we plan to chase alongside < > additional collaborators. That market encompasses the < > area, where roughly 70,000 thalassemia patients live, along with several of the top treatment sites from our clinical trials. Now let me share an update regarding the ongoing PYRUKYND launch in PK deficiency. During the first quarter of 2024, net PYRUKYND revenue reached $8.2 million, up from $7.1 million in the fourth quarter of 2023. Within the U.S., 188 patients in total have finished a prescription enrollment form, 10 of them in the first quarter of 2024, which is a 6% rise over the prior quarter. That has converted into 120 patients on therapy on a net basis, a 10% gain over the prior quarter. Those receiving therapy keep coming from an expanding, varied prescriber base made up of 162 physicians and reflect a wide demographic < > range matching the adult PK deficiency population in the U.S. We stay encouraged by how persistent patients are with treatment and keep our focus on efficiently pinpointing providers likely to treat individuals with PK deficiency. We think these capabilities will keep getting stronger throughout the current launch, with efficient targeting analytics, patient and HCP awareness and education, and patient access offering a solid foundation to maximize potential future U.S. launches of mitapivat in thalassemia in 2025 and in sickle cell disease in 2026. Most importantly, Agios is again immensely proud to be pioneering a potential new therapy for these 2 underserved patient populations. With that, I'll hand the call over to Cecilia.

Cecilia Jones

executive
#5

Appreciate that, Tsveta. You can find our Q1 2024 financial results in this morning's press release, and our 10-Q, being filed later today, will carry additional detail. Let me pause here to give a bit of context and walk through several key items. Net PYRUKYND revenue for the first quarter of 2024 came in at $8.2 million, which is $2.6 million higher than the first quarter of 2023. As with other rare disease launches, gross to net has run, and should continue to run, between 10% and 20% on an annual basis. Cost of sales during the quarter totaled $0.6 million. R&D expenses for the first quarter reached $68.6 million, up $1.3 million versus the first quarter of 2023. That rise came mainly from higher process development expenses, partly offset by lower workforce related expenditures. SG&A expenses for the first quarter were $31 million, an increase of $2.6 million over the prior year quarter. The main driver was growth in commercial-related activities as we get ready for possible approval of PYRUKYND in thalassemia. Keep in mind that, through the divestiture of our oncology business to Servier, we kept rights to a potential $200 million milestone tied to FDA approval of vorasidenib, plus 15% royalties on potential U.S. net sales. We closed the quarter with roughly $714.3 million in cash, cash equivalents and marketable securities. We believe this balance, along with anticipated product revenue, interest income and the potential vorasidenib milestone, will let the company fund operating expenditures and capital expenditures through multiple value-creating milestones and at least into 2026; that guidance excludes cash inflows that might stretch our runway past 2026, such as potential royalties or royalty monetization from vorasidenib, commercializing mitapivat outside the U.S. via one or more partnerships, or other potential strategic business or financial agreements. Creating shareholder value remains our focus, whether through proactively managing our cost base or applying a disciplined cash allocation approach, and we are preparing to support possible future launches of PYRUKYND. With more potential value-creating milestones coming in the near term, I'm confident our strong balance sheet lets us execute from a position of strength. I'll hand the call back to Brian now for his closing remarks.

Brian Goff

executive
#6

Appreciate that, Cecilia. Because mitapivat works through a unique, differentiated mechanism that boosts the health of red blood cells, and because our clinical dataset contains favorable results across 3 hemolytic anemias, we think this drug is positioned to be first-in-class as well as best-in-class across multiple indications, with the possibility of growing into a multibillion-dollar franchise. Our team has kept delivering meaningful advances, and that makes me extremely proud; going forward, those catalyst-rich 24 months ahead of us genuinely excite me. While we keep moving toward making our vision a reality — that of a top rare disease company — we will keep working to be careful stewards of the balance sheet and to assess worthwhile chances to create value. Last, my thanks go out to every one of our employees for the effort and commitment they bring to our mission of creating and providing transformative medicines that lift up and lengthen the lives of people who have rare diseases, plus all of our partners, among them the patients, physicians, caregivers and participants in our clinical development programs. With that said, the call is now open for questions.

Gregory Renza

analyst
#7

Excellent. Brian and the rest of the team, nice work on the progress. Brian, we really do value the added specificity and the timeline you've given for the ENERGIZE-T data. I'm just wondering, now that you've tightened it at least from midyear down to the second quarter, could you say a little about what factors are relevant at this point? What still has to get done, and perhaps what's influencing the ability to bring it into that narrower, earlier window in the second quarter? And on a related note, could you just walk us through the mechanics of how patients transition into the open-label extension?

Brian Goff

executive
#8

Absolutely. Thank you, Greg. I'll hand it to Sarah to cover the mechanics. What I will say is that we're eagerly anticipating these data. It's a really remarkable moment here at Agios, because anyone who has tracked us — and Greg, I know you've been along for the ride — is aware that we were thrilled to receive the ENERGIZE data back in January; and this trial, ENERGIZE-T, runs twice as long. That one — ENERGIZE lasted 24 weeks, whereas this one goes 48 weeks, and we recognize there's substantial interest, so we were happy to provide, as you mentioned, somewhat finer detail regarding the timing. Sarah, would you like to address the mechanics?

Sarah Gheuens

executive
#9

Right. So the timing's level of detail really comes down to the patients. With the final few patients in the study, whether they chose to move into the open-label extension matters, because as you're aware, had a patient opted against entering open label, they'd have to taper off the drug and then complete a safety follow-up visit, and that essentially sets the timeline, producing roughly a 7-week gap between possible readouts. So at this point we have far greater precision on that kind of information, which lets us tighten our time frame; that's the reason we updated our guidance today; we're extremely enthusiastic about where things stand at this moment, and the team remains highly focused on delivering the next steps for this particular trial.

Brian Goff

executive
#10

Right, so what we're looking at here mirrors precisely what happened a year ago, when the RISE UP Phase II results in sickle cell disease were disclosed, and naturally the same situation applied to ENERGIZE back in January. The broader point I want to leave you with is this: as we mentioned during our prepared remarks, the plan is to submit both trials jointly, aiming for a label covering the entire thalassemia population across every subtype. Having said that, we're obviously eager to see the data, yet we already occupy a notably strong position thanks to what ENERGIZE showed and, as Tsveta pointed out, that already accounts for 2/3 of patients in the U.S. who have nontransfusion-dependent thalassemia.

Gregory Renza

analyst
#11

Thanks, Brian. Perhaps a quick follow-up, more broadly, about the competitive landscape. Obviously, with competition in PK activation, and with Novo's etavopivat possibly now having some timelines set. What's your take on that? How are you viewing the landscape over the longer term? You're clearly moving quickly. But when you consider the competition between the 2 offerings for patients in the end.

Brian Goff

executive
#12

Yes. Appreciate the question. I'd say certainly, we're very proud of being the global leader when it comes to PK activation. And given some recent competitive news that's become public, particularly regarding the other PK activator, etavopivat, from Novo Nordisk, we observed the latest revised timelines. That's why, in our prepared remarks, you heard us say we've frequently stated that our confidence in a best-in-class position is strong. Our confidence keeps growing now in both thalassemia and, of course, sickle cell disease, with potential to be first-in-class, and all of that means this franchise, with mitapivat, could reach multibillion-dollar potential. We're in a truly significant position of strength.

Tsveta Milanova

executive
#13

Yes, certainly. If we look at this from a commercial standpoint for thalassemia, we're clearly well ahead of them—they're set to read out data from their Phase II trial in 2026, and we're unsure how committed they are to a Phase III. So with thalassemia, we're really enthusiastic about leading the charge in offering treatment choices to every thalassemia patient. In sickle cell disease, we're just as excited, and enrollment for our Phase III clinic trial is moving forward. All is proceeding according to plan. What we < > did, they're anticipating sickle cell disease data in 2027, which will place them behind. Our expected launch in 2026 gives us another chance to essentially deliver the first innovative product capable of reaching every clinically and commercially meaningful endpoint—hemoglobin improvement, VOC reduction, and better quality of life—so we're thrilled to keep advancing.

Brian Goff

executive
#14

And here's where Tsveta's know-how really comes into play — she has serious depth when it comes to launching rare disease treatments; this is the kind of moment you wait for your whole career, a real opportunity to make a difference for patients and for thalassemia, that situation in particular. Plus, that launch could arrive as soon as next year, so it's not far off.

Divya Rao

analyst
#15

Divya here, filling in for Mark. Regarding the thalassemia study — the one for transfusion-dependent thalassemia that's on the horizon — could you take us through the assumptions behind the statistical power for the primary endpoint? Then I've got one more question after that.

Brian Goff

executive
#16

Of course. Appreciate it, Divya. Sarah, would you like to handle that one?

Sarah Gheuens

executive
#17

Right, so the assumptions about statistical power behind that figure haven't been walked through in depth. That said, we've obviously drawn on every piece of data we could get our hands on, so that the financial case for running this study is solid, and we feel good about both the primary endpoint and the sample size we landed on. As you're aware, the primary endpoint on its own is the 50% reduction across any rolling 12-week period, and our view is that this can deliver a highly meaningful read on how much transfusion burden gets cut for patients with thalassemia.

Divya Rao

analyst
#18

Understood. Then, as a quick follow-up, regarding AG-946, should we still anticipate the complete results from the Phase IIa study at some point in 2023?

Sarah Gheuens

executive
#19

We haven't discussed the timing for putting out the Phase IIa data, since the team is evaluating the optimal chance for doing that at the ideal conference, and also aligning with when the Phase IIb is being set up and running; so, we're really concentrated on that, really enthusiastic; a milestone exists for us tied to the Phase IIb during this year. And thus, we remain on schedule to achieve it.

Eric Schmidt

analyst
#20

Congratulations on everything that's been accomplished. I have perhaps 2 brief questions. To start, for Brian and Sarah regarding the thalassemia submission. First, could you verify if this will be an NDA submission? It sounds as though that submission is already being readied. To be quite precise, should the TDT trial somehow come up short, would a filing then be needed for patients who are nontransfusion-dependent? Is that accurate?

Sarah Gheuens

executive
#21

Thank you for asking. Our aim is to submit both studies as one. As you're aware, data from the initial portion is already in hand. So our submission preparations are, in fact, fully in motion, and the team remains on schedule to deliver. At this point we await that second study. The reality is we already possess strong data covering 2/3 of the patient population. Naturally, we're hoping the second study succeeds and turns this into a compelling story. Should that study come up short, it really hinges on what the data reveal and how we'd choose to proceed. Still, our plan is to submit for every thalassemia patient and secure that wide indication.

Eric Schmidt

analyst
#22

I appreciate you clearing that up, Sarah. I have one more question, this one about the Phase III sickle cell trial that is currently recruiting. Could you share any details on how it's progressing? Also, what portion of the trial has been enrolled so far, or perhaps any expected dates for next year?

Sarah Gheuens

executive
#23

Absolutely. The RISE UP study has us all very enthusiastic. Things are moving along nicely, and our team deserves a lot of credit for getting this trial fully operational, and our enrollment is where we want it to be, so we fully anticipate reaching complete enrollment by the close of this year; we don't provide guidance on particular figures for particular weeks or months. In a large Phase III trial, circumstances shift very quickly, so our guidance focuses on larger milestones.

Eric Schmidt

analyst
#24

Well done once more.

Alec Stranahan

analyst
#25

We have a few things to ask. Starting with a business-related item. If transfusion and nontransfusion are both approved for the label, is there any basis to believe your commercial approach might need to be adjusted for these two categories of patients? Or would it essentially remain unchanged, since the same physicians are probably treating them? Then I have another question after that.

Brian Goff

executive
#26

Of course. Appreciate it, Alec, and glad to have you on the Agios call; and Tsveta, would you like to kick things off?

Tsveta Milanova

executive
#27

Certainly. The results we've seen from ENERGIZE have us very encouraged. And like I mentioned, we're waiting with great anticipation for the ENERGIZE-T readout too. On the launch side, we're fully engaged in getting ready; our view is that the unmet need runs higher in both groups of patients — those who depend on transfusions and those who don't. A great deal of information informs how we're shaping that launch strategy, such as claims data and the availability of ICD-10 codes; and our basic plan is to engage both patient groups the same way, since the disease has the same underlying pathophysiology and the two populations are connected. And as you pointed out, there's overlap when it comes to who prescribes. Naturally, you'll find somewhat greater concentration among the nontransfusion-dependent patients in the KOL and center of excellence settings, and somewhat more of the nontransfusion-dependence out in the community setting, though that wouldn't alter how we deploy, communicate, and educate.

Brian Goff

executive
#28

One more point I'd make is that folks who depend on transfusions clearly come in to see their clinicians on a more predictable schedule than those who don't need transfusions tend to. Even so, it makes me genuinely proud that Tsveta and the rest of the team have planned for every possible situation.

Alec Stranahan

analyst
#29

All right, that's great. Then I have a single follow-up regarding the opportunity outside the United States. You've mentioned, as I understand it, that the approach would probably involve working with a partner across geographies beyond the U.S.; is there anything more you can share regarding the expected timing or the size of that ex-U.S. opportunity, purely from a modeling standpoint for us?

Tsveta Milanova

executive
#30

Of course. Beyond getting everything ready to launch here in the U.S., we are simultaneously looking hard for the ideal collaborator to help us get the most out of the opportunity outside the U.S. As we've noted a number of times, the Gulf region ranks as a top priority for us, since 70,000 thalassemia patients live there. Sarah and her team are also actively getting regulatory submissions ready across those regions so we can file as fast as we can, which will let us — and we will share an update the moment we have productive talks and settle on a partner — but our position is very strong, particularly given the positive ENERGIZE data, which lets us hold really high-caliber conversations with partners possessing deep regional expertise; this excites us since our clinical trials were likewise conducted there, and there's considerable KOL advocacy plus experience with thalassemia and mitapivat, making it just as thrilling a market as the U.S. launch.

Tessa Romero

analyst
#31

Here's something for Cecilia. I'm just wondering — could you take us through what's driving the balance sheet in both directions, and how you're thinking about ways you might stretch that runway further? What's your current view on that? We saw that you put something in today's release — how much interest is there, specifically, in a possible royalty monetization tied to vorasidenib? Then, on the partnering front, outside the U.S., just to be clear given the comments made here, might that happen during this year?

Cecilia Jones

executive
#32

I'll kick things off, and then we can chime in on the ex-U.S. piece too. So yes, our guidance has been that our cash lasts at least into 2026. And we deliberately excluded a few items you brought up; I'll address some of them, but there are also other elements — for instance, we clearly keep managing our cost bases carefully and with discipline. We're now beginning launch preparations, though we held off until we were certain we had the data before moving forward; regarding vora, that's one more possibility we examined as we assess ways to stretch our runway; we — as we said in the prepared remarks. So Servier made a public announcement that the FDA accepted their filing, with a PDUFA date of August 20th. And just to remind everyone, there's a $200 million milestone tied to FDA approval plus 15% royalties on U.S. net sales for that, and we'll look at opportunities to sell it — either the entire amount or some portion — as one way to extend the runway, just as we'll do with other items. The other possibility, or the other element we excluded, as you noted, is the ex-U.S. portion, which can take various shapes and forms, and that's partly why we left it out. On timing, obviously, the teams are working to secure the best partner, and that reflects where the patients are, as Tsveta described, and we obviously want to move as quickly as we can to get those patients access.

Salveen Richter

analyst
#33

This is Lydia calling in for Salveen. Regarding the ENERGIZE-T data that's coming up, can you talk about the clinical threshold for success and what you'd like to observe when it comes to that proportion of patients experiencing a decrease in transfusion burden? Would it be reasonable for us to think this readout might look like the previous ENERGIZE readout?

Sarah Gheuens

executive
#34

Appreciate the question. So regarding the ENERGIZE-T readout, naturally, our hope is to achieve our primary endpoint with a reduction — a 50% decrease during any rolling 12-week period; we haven't discussed the specific delta we're aiming for between placebo and mitapivat. As for the study itself, it is, naturally, carefully designed so it can achieve the primary endpoint given the assumptions that form the basis of that design. What we do know, however, is that there's the clinical trial threshold we're targeting — that 50% reduction. Yet in actual practice, we recognize the bar might in fact be lower, since what the compound — the product would accomplish is essentially eliminate certain clinic visits for patients when they're able to forgo transfusions, and that would significantly affect quality of life for patients with transfusion-dependent thalassemia. I believe Tsveta may be able to say a bit more about what we anticipate in actual practice.

Tsveta Milanova

executive
#35

Sure. You brought up that the clinical bar matters a lot from a regulatory standpoint. But what we're hearing from both patients and clinicians regarding utilization is that they'll be seeking a decrease in transfusion burden even if it's at a reduced rate, and they'll view that as clinically meaningful. Since even stretching out how often transfusions are needed by 1 week, on a stations, essentially, it's quite meaningful on an actual health care system level as well, and for clinicians it's very meaningful. So we're extremely excited to see the data and are actively getting ready for launch.

Brian Goff

executive
#36

One more thing I'd like to mention — clearly, our aim in the ENERGIZE-T trial is statistical significance. Based on what we've seen before, people may be tempted to compare across studies. I'd like to stress that mitapivat's profile is so strong overall that numerical matching isn't really required. What matters is achieving statistical significance on the endpoint — that's our goal. Still, since this is an oral treatment, patients are already largely spared clinic visits compared with other options, namely luspatercept. And on top of everything else, that's yet another genuine benefit from the patient's perspective.

Danielle Brill

analyst
#37

To start, I'd like to ask about what placebo response you're expecting for ENERGIZE-T in the luspatercept trial. As far as I understand, the placebo response rate, based on how you defined it for your primary, came in at roughly 6%. I'm curious what your thinking is on how the placebo group manages to reach that degree of reduction, and do you anticipate a comparable result in ENERGIZE-T? Then, a quick follow-up. I'm just wondering how you intend to announce the data. Will it come as a top line PR? Or could it be that you present at EHA?

Sarah Gheuens

executive
#38

Yes; so when you measure transfusion, fluctuation is always present. So 6% for the placebo with respect to the primary endpoint definition is a very reasonable observation. And that is also because in clinical practice, sometimes patients get transfused based on symptom presence and things like that; so in regards to how we are going to announce the data, yes, we typically do a top line release via press release; we will not be able to present data at EHA because the time frame for submission of data there is long gone. So that will — that is not in the plan.

Brian Goff

executive
#39

Much appreciated, Norma, and many thanks to all of you for joining us on this call today. I believe it is — my hope is that it is evident. This marks a highly thrilling period here at Agios. Our view is that we are positioned strongly to bring breakthrough new treatments to patients while also generating considerable value over the long term for shareholders. So once more, thank you, and we are eager to connect with each of you again before long.

Operator

operator
#40

That wraps up the call for today. We appreciate everyone joining us. You're free to hang up at this point. Have a great day, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.